was: Composite fair value: $89.47 → signal-adjusted: $83.15 vs current price $77.59 (+7.2%). Methods disagree — mixed signals. Treat the composite with caution.

now: Composite fair value: $96.68 → signal-adjusted: $91.71 vs current price $79.44 (+15.4%). Methods disagree — mixed signals. Treat the composite with caution. Market prices in less growth than projected — potential for re-rating if growth materialises.

was: Undervalued on quality-adjusted basis — fair value $90-95 on normalized 16-18x multiple, but thesis hinges on Librela stabilization; starter position at $77 with adds below $72 if Q2 disappoints.

now: Modestly undervalued but execution-gated — fair value $82-88 on current trajectory, starter position warranted at $79 given insider buys and 6.8% FCF yield, but the $96 synthesis target requires growth re-acceleration that the Q1 2026 print actively contradicts.

was: I agree with Opus — undervalued at $77.59, but I'd peg fair value closer to $85, considering potential growth headwinds and the need for a cautious watch on key product lines like Librela.

now: I disagree with Opus's "modestly undervalued" call at $79.44; I see Zoetis as fairly valued in the $75-85 range, given the decelerating growth and potential market headwinds, with the need for clear evidence of growth re-acceleration to justify a higher valuation.

was: The market has violently re-rated Zoetis from premium pharma-like multiple (likely 25-30x) to commodity/cyclical territory (current price suggests ~10-12x if earnings held). This de-rating overwhelmed improving fundamentals. Either the market fears: (1) generics eroding key companion animal franchises, (2) livestock demand collapse, (3) international exposure to emerging market currency crisis, or (4) this was indiscriminate selling in high-multiple healthcare names. The stable financials suggest market overreaction rather than fundamental deterioration.

now: The market is currently pricing Zoetis as if its moat has eroded or growth has permanently slowed. The 54% drawdown from 52-week highs implies either a major multiple de-rating (from ~35-40x P/E to ~22-25x) or concern about competitive pressure, possibly from generic animal drugs or Elanco's turnaround efforts. At $79, the stock appears to discount very little growth premium, suggesting investors have shifted from pricing a perpetual compounder to pricing a mature, low-growth pharma asset. The question is whether this de-rating is justified or creates opportunity.

was: Patent cliffs on blockbuster companion animal products (Simparica, Apoquel) with generic competition eroding premium pricing · Livestock segment exposure to agricultural commodity cycle - if meat prices collapse or disease outbreak occurs (ASF, Avian flu) · International revenue concentration (likely >40%) creates FX headwinds if dollar strengthens or emerging markets devalue · Regulatory risk if antibiotics/vaccines face new restrictions due to antimicrobial resistance concerns · Companion animal market saturation - US pet ownership may have peaked post-COVID, reducing new customer acquisition

now: Generic competition in key livestock products (especially parasiticides) could erode pricing power faster than new product pipeline can offset · Elanco operational turnaround—if the main competitor fixes execution, it could pressure Zoetis's market share gains and pricing · Livestock cycle downturn—prolonged low cattle/hog prices reduce farmer willingness to pay for premium animal health products · Regulatory changes allowing direct-to-consumer animal drug sales, bypassing the veterinary channel that provides Zoetis's distribution moat · Patent cliffs on major products (need to verify product lifecycle) without adequate pipeline replacement

was: New product launches in companion animal space (monoclonal antibodies, gene therapies for pets) - pharma-like innovation pipeline · M&A to consolidate animal health industry - Zoetis could acquire ELAN or smaller players to eliminate competition · Emerging market livestock growth (China, India) as protein consumption rises with GDP growth · Parasiticide market expansion if climate change extends flea/tick seasons geographically · Clarification on debt/capital structure (data shows $0 - if actually underleveraged, could initiate buybacks to support stock)

now: Continued companion animal market expansion—pet humanization driving premium spending on preventative care and diagnostics · New product approvals, particularly in high-margin companion animal segment (monoclonal antibodies, novel parasiticides) · Market share gains if Elanco continues to struggle with integration/execution · Margin expansion from manufacturing scale and mix shift toward companion animal (higher gross margin segment) · Capital deployment—M&A to enter adjacent niches or accelerated buybacks given FCF generation and low current valuation